Novo Seeds represents Novo Holdings early stage investment arm; Novo Holdings is a wholly owned subsidiary of Danish biopharma giant Novo Nordisk Foundation. Novo Seeds published its 2018 results—a record year including six new investments, two portfolio companies closed major financing rounds; the launch of the REPAIR Impact Fund and significant expansion of the team. TrialSite News includes the newsletter below. Novo Seeds reviewed approximately 400 opportunities in 2018. They made six investments ranging in size from €250,000 to €12.5 million.